AC
RGLS

Ascend Capital’s Regulus Therapeutics RGLS Stock Holding History

Ascend Capital’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$207K Sell
8,758
-145
-2% -$4.78K 0.01% 162
2018
Q2 		$705K Buy
8,903
+556
+7% +$46K 0.03% 170
2018
Q1 		$718K Sell
8,347
-103
-1% -$13.8K 0.03% 196
2017
Q4 		$1.05M Buy
+8,450
New +$1.07M 0.04% 192

Other funds holding RGLS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SDIC
South Dakota Investment Council Sioux Falls, South Dakota $5.24B AUM 22.1% 1-Year Est. Return

Ascend Capital's RGLS Position: Q3 2018 in Review

Ascend Capital reduced its Regulus Therapeutics (RGLS) stake by 1.6% in Q3 2018, selling an estimated $4.78K and leaving 8,758 shares worth $207K. The position accounts for 0.01% of the portfolio, ranked #162.

Ascend Capital first reported a position in RGLS in Q4 2017 and has held it in 4 quarters since. The position peaked at $1.05M in Q4 2017. 36 funds tracked by Wall St. Rank hold RGLS as of Q3 2018.

  • Ascend Capital held 8,758 shares of Regulus Therapeutics worth $207K as of Q3 2018.
  • Ascend Capital sold 145 Regulus Therapeutics shares in Q3 2018, an estimated $4.78K.
  • Regulus Therapeutics made up 0.01% of Ascend Capital's portfolio in Q3 2018, its #162 holding.
  • Ascend Capital first reported a position in Regulus Therapeutics in Q4 2017 and has held it in 4 quarters since.
  • Ascend Capital's Regulus Therapeutics position peaked at $1.05M in Q4 2017.
  • 36 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q3 2018.

Based on Ascend Capital's 13F filing for Q3 2018, filed 13 Nov 2018.